Navigation Links
ThromboGenics NV: Business Update
Date:5/14/2009

associated with current anti-coagulant therapy.

Patient recruitment for this trial is on track and it is anticipated that this study will conclude by the end of 2010.

TB-403 - Anti-cancer: Partnership with Roche progressing well - Phase Ib trial results expected by the end of 2009. In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). In January, 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

The clinical development of TB-403 is also progressing well with the results of a Phase Ib trial expected by the end of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.

Microplasmin for Vascular Disease - Initial partnering discussions. After the encouraging Phase II results presented last year, ThromboGenics is continuing to look for a partner to continue the further development of microplasmin for the treatment of stroke.

Pre-Clinical Highlights

Anti-VPAC - EUR3.2 million Grant Awarded to ThromboGenics for the continued development of Anti-VPAC for the treatment of thrombocytopenia - At the end of February 2009, ThromboGenics was awarded a grant of up to EUR3.2 million for the continued development of its Anti-VPAC1 (Vasoactive Intestinal Peptide/Pituitary Adenylyl Cyclase-Activating Peptide Receptor 1) antibody for the treatment of thrombocytopenia (low platelet count) after chemotherapy.

The grant was received from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT) and is based on the successful completion
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... The science of light and how ... more than 200 primary students in a traveling program ... of Otago Physics Department and funded by an ... of the university’s OSA/SPIE Student Chapter visited six primary ... children from small, rural schools hands-on lessons in optics ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 The November ... available as an open access journal featuring the following ... fluorescent proteins to preserve photoresponsiveness in the retina , ... fluorescent in situ hybridization using chromogenic substrates in zebrafish ... DNA, RNA, and protein electrophoresis , Nuclear ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/18/2014)... 17, 2014 RPS Diagnostics (RPS®) ... – today announces its third annual partnership of ... Get Smart About Antibiotics Week from November 17-23. ... national campaign designed to highlight the coordinated efforts ... non-profit and for-profit partners to provide education about ...
Breaking Biology Technology:Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... DIEGO, Oct. 6 Gen-Probe Incorporated (Nasdaq: GPRO ... agreement to acquire Prodesse, Inc., a privately held leader ... for approximately $60 million in cash. Gen-Probe,s purchase ... Prodesse achieves certain financial and regulatory milestones in 2010 ...
... Oct. 6 Particle Sciences has ... to develop technology for a key Dow Corning product development ... remarked, "This is a little outside our normal focus of ... expect to provide a novel and robust solution that allows ...
... , ATLANTA, Oct. 6 CryoLife, Inc., ... and cardiovascular tissue processing company, today announced that it has ... and Drug Administration (FDA) for its CryoValve® SG aortic human ... in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve ...
Cached Biology Technology:Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 2Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 3Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 4Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments 5Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 2CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 3CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves 4
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... seem, wastewater flushed down toilets and sinks is getting a ... to produce electricity, according to the latest video in the ... by the world,s largest scientific society, the video is at ... the video, points out that sewage treatment traditionally has been ...
... available in German . ... point to an infection with the bacterium Yersinia . ... apparatus called injectisome. For the first time, an international team ... Research (HZI) in Braunschweig, Germany, has unraveled this molecular syringe,s ...
... has been awarded a $2 million federal grant to ... that can be grown together to create a high-yield, ... National Science Foundation funding for the project begins ... effort will involve growing various combinations of lake algae ...
Cached Biology News:3-D molecular syringes 23-D molecular syringes 3U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 2U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 3U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 4U-M researchers land $2M grant to 'cooperate with nature' on growing algae for energy 5
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
... Freedom EVO96R and Freedom EVO384R are ... instrument, available in three different sizes, with ... arm. They deliver significant time saving, with ... an easy setup of your assays with ...
Special grade: for electrophoresis...
... two sets of glass plates, bar clamp, ... Special features of these units are:, safety ... buffer reservoirs , upper and lower reservoirs ... and safe disposal of buffer solutions , ...
Biology Products: